CD56 PE

BD™ CD56 PE

Name: CD56 PE
Brand: CD56 PE
SKU: 345812

Clone NCAM16.2 (also known as NCAM 16) (CE_IVD)

Spectrum Viewer

Protocol Library

Scientific Resources

Catalog No:345812

Your Price:Sign In

Unit:EA (1 Each)

Size:

50 Tests

Quantity:

Add to Cart

Save To Shopping List Request Bulk Reagent Quote

Product Details

Brand: BD™

Alternative Name: NCAM1; NCAM-1; NCAM; Leu-19; Neural cell adhesion molecule 1; NKH1; MSK39

Reactivity: Human

Isotype: Mouse BALB/c IgG2b, κ

Immunogen: Immunoaffinity-enriched adult human brain NCAM

Application: Flow cytometry

Concentration: 12.5 μg/mL

Vol. Per Test: 20 μL

Workshop Number: V NK60

Entrez Gene ID: 4684

RRID: AB_2629216

Storage Buffer: Phosphate buffered saline with gelatin and 0.1% sodium azide.

Regulatory Status: CE_IVD

Preparation And Storage

The antibody reagent is stable until the expiration date shown on the label when stored at 2° to 8°C. Do not use after the expiration date. Do not freeze the reagent or expose it to direct light during storage or incubation with cells. Keep the outside of the reagent vial dry.

Do not use the reagent if you observe any change in appearance. Precipitation or discoloration indicates instability or deterioration.

Data Sheets

Safety Data Sheet

Instruction For Use (IFU)

345812 Rev. 1

Antibody Details

NCAM16.2

CD56 is intended for in vitro diagnostic use in the identification of cells expressing CD56 antigen, using a BD FACS™ brand flow cytometer. The flow cytometer must be equipped to detect light scatter and the appropriate fluorescence, and be equipped with appropriate analysis software for data acquisition and analysis. Refer to your instrument user’s guide for instructions.

345812 Rev. 1

Format Details

R-Phycoerythrin (PE), is part of the BD family of Phycobiliprotein dyes. This fluorochrome is a multimeric fluorescent phycobiliprotein with excitation maximum (Ex Max) of 496 nm and 566 nm and an emission maximum (Em Max) at 576 nm. PE is designed to be excited by the Blue (488 nm), Green (532 nm) and Yellow-Green (561 nm) lasers and detected using an optical filter centered near 575 nm (e.g., a 575/26-nm bandpass filter). As PE is excited by multiple lasers, this can result in cross-laser excitation and fluorescence spillover on instruments with various combinations of Blue, Green, and Yellow-Green lasers. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.

Format: PE

Excitation Max: 496 nm, 566 nm

Emission Max: 576 nm

345812 Rev.1

Citations & References

View Development References

Development References (15)

Centers for Disease Control. Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in healthcare settings. MMWR. 1988; 37:377-388. (Biology).
Clinical Applications of Flow Cytometry: Quality Assurance and Immunophenotyping of Lymphocytes: Approved Guideline. NCCLS document H42-A. 1998. (Biology).
Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Rothe G, Schmitz G. Leukemia. 1996; 10:877-895. (Biology).
Cunningham BA, Hemperly JJ, Murray BA, Prediger EA, Brackenbury R, Edelman GM. Neural cell adhesion molecule: structure, immunoglobulin-like domains, cell surface modulation, and alternative RNA splicing. Science. 1987; 236(4803):799-806. (Biology). View Reference
Jackson AL, Warner NL. Preparation, staining, and analysis by flow cytometry of peripheral blood leukocytes. In: Rose NR, Friedman H, Fahey JL, ed. Manual of Clincial Laboratory Immunology, Third Edition. Washington DC: American Society for Microbiology; 1986:226-235.
Lanier LL, Chang C, Azuma M, Ruitenberg JJ, Hemperly JJ, Phillips JH. Molecular and functional analysis of human natural killer cell-associated neural cell adhesion molecule (N-CAM/CD56). J Immunol. 1991; 146(12):4421-4426. (Biology). View Reference
Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol. 1986; 136(12):4480-4486. (Biology). View Reference
Loughran TP, Jr. Clonal diseases of large granular lymphocytes. Blood. 1993; 82:43844. (Biology).
Macon WR, Williams ME, Greer JP, et al. Natural killer-like T-cell lymphomas: aggressive lymphomas of T-large granular lymphocytes. Blood. 1996; 87:1474-1483. (Biology).
NCCLS document. 2001. (Biology).
Ocqueteau M, Orfao A, Almeida J, et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol. 1998; 152:1655-1665. (Biology).
Okuno SH, Tefferi A, Hanson C, Katzmann JA, Li CY, Witzig TE. Spectrum of diseases associated with increased proportions or absolute numbers of peripheral blood natural killer cells. Br J Haematol. 1996; 93:810-812. (Biology).
Schubert J, Lanier LL, Schmidt RE. Knapp W, Dörken B, Gilks WR, et al, ed. Leucocyte Typing IV: White Cell Differentiation Antigens. New York, NY: Oxford University Press; 1989:699-702.
Stelzer GT, Marti G, Hurley A, McCoy PJ, Lovett EJ, Schwartz A. US-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry. 1997; 30:214-230. (Biology).
Van Camp B, Durie BGM, Spier C, et al. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). Blood. 1990; 76:377-382. (Biology).

View All (15)

345812 Rev. 1

Please refer to Support Documents for Quality Certificates

Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described

Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Documents are subject to revision without notice. Please verify you have the correct revision of the document, and always refer back to BD's eIFU website for the latest and most up to date information.